entacapone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
catechol-O-methyltransferase (COMT) inhibitors	1018	130929-57-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: entacapone entacom comtess	Entacapone is a selective and reversible inhibitor of COMT. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease. Molecular weight: 305.29 Formula: C14H15N3O5 CLOGP: 2.66 LIPINSKI: 0 HAC: 8 HDO: 2 TPSA: 130.38 ALOGS: -3.58 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

entacapone
entacom
comtess

Entacapone is a selective and reversible inhibitor of COMT. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease.

Molecular weight: 305.29
Formula: C14H15N3O5
CLOGP: 2.66
LIPINSKI: 0
HAC: 8
HDO: 2
TPSA: 130.38
ALOGS: -3.58
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.02 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.20 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	87.35 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	42 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.27 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 18, 2011	EMA	Teva Pharma B.V.
Oct. 19, 1999	FDA	ORION PHARMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dyskinesia	492.12	25.42	155	4724	31847	63452296
Hallucination	277.45	25.42	117	4762	54700	63429443
On and off phenomenon	203.29	25.42	43	4836	1792	63482351
Hallucination, visual	152.79	25.42	57	4822	19241	63464902
Dystonia	147.78	25.42	51	4828	13768	63470375
Psychotic disorder	120.28	25.42	52	4827	25660	63458483
Therapeutic response shortened	108.47	25.42	39	4840	11849	63472294
Muscle rigidity	105.95	25.42	38	4841	11462	63472681
Sudden onset of sleep	97.03	25.42	19	4860	534	63483609
Compulsive shopping	96.85	25.42	20	4859	739	63483404
Impulse-control disorder	96.05	25.42	20	4859	770	63483373
Mutism	86.73	25.42	21	4858	1609	63482534
Delusion	86.04	25.42	33	4846	11984	63472159
Acute psychosis	82.32	25.42	22	4857	2503	63481640
Freezing phenomenon	81.26	25.42	19	4860	1253	63482890
Dopamine dysregulation syndrome	76.03	25.42	13	4866	167	63483976
Aggression	67.72	25.42	34	4845	23464	63460679
Tremor	64.23	25.42	64	4815	132175	63351968
Akinesia	62.12	25.42	16	4863	1577	63482566
Stoma site discharge	62.07	25.42	16	4863	1582	63482561
Stereotypy	58.46	25.42	12	4867	430	63483713
Camptocormia	56.56	25.42	11	4868	298	63483845
Gait disturbance	55.07	25.42	69	4810	183109	63301034
Fall	51.77	25.42	101	4778	392233	63091910
Parkinsonism hyperpyrexia syndrome	50.78	25.42	9	4870	144	63483999
Dysphagia	50.78	25.42	47	4832	88538	63395605
Orthostatic hypotension	49.07	25.42	32	4847	36128	63448015
Gambling	46.52	25.42	9	4870	237	63483906
Parkinsonian gait	45.29	25.42	10	4869	509	63483634
Impulsive behaviour	43.23	25.42	12	4867	1571	63482572
Agitation	42.82	25.42	36	4843	59721	63424422
Psychomotor hyperactivity	41.58	25.42	19	4860	10644	63473499
Confusional state	41.52	25.42	69	4810	236311	63247832
Therapeutic product effect variable	41.49	25.42	11	4868	1212	63482931
Hyperkinesia	37.88	25.42	11	4868	1693	63482450
Bradykinesia	36.24	25.42	14	4865	5174	63478969
Pleurothotonus	35.81	25.42	10	4869	1339	63482804
Logorrhoea	33.68	25.42	11	4868	2499	63481644
Wrong technique in product usage process	33.64	25.42	32	4847	62308	63421835
Neuroleptic malignant syndrome	33.42	25.42	17	4862	12039	63472104
Speech disorder	32.28	25.42	26	4853	40603	63443540
Stoma site erythema	31.99	25.42	9	4870	1238	63482905
Gambling disorder	31.95	25.42	9	4870	1243	63482900
Balance disorder	30.56	25.42	35	4844	84387	63399756
Rash	29.75	25.42	4	4875	560867	62923276
Stoma site pain	29.17	25.42	8	4871	1002	63483141
Abnormal behaviour	29.15	25.42	19	4860	21407	63462736
Eating disorder	28.69	25.42	18	4861	18998	63465145
Parkinson's disease	27.68	25.42	8	4871	1211	63482932
Delirium	27.37	25.42	26	4853	50515	63433628
Parkinsonism	26.85	25.42	14	4865	10425	63473718
Femoral neck fracture	26.52	25.42	13	4866	8510	63475633
Posture abnormal	26.44	25.42	9	4870	2323	63481820
Stoma site infection	26.11	25.42	7	4872	805	63483338

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dyskinesia	311.86	24.20	129	6759	22284	34927759
Hallucination	271.04	24.20	152	6736	51346	34898697
On and off phenomenon	233.79	24.20	61	6827	2436	34947607
Hypersexuality	227.98	24.20	54	6834	1439	34948604
Hallucination, visual	215.97	24.20	93	6795	17698	34932345
Gambling disorder	212.10	24.20	52	6836	1608	34948435
Muscle rigidity	182.33	24.20	71	6817	10447	34939596
Freezing phenomenon	146.05	24.20	38	6850	1498	34948545
Delusion	117.93	24.20	55	6833	12580	34937463
Fall	104.34	24.20	161	6727	202724	34747319
Dysphagia	101.91	24.20	90	6798	62291	34887752
Parkinson's disease	96.63	24.20	27	6861	1397	34948646
Bradykinesia	80.82	24.20	30	6858	3863	34946180
Neuroleptic malignant syndrome	75.71	24.20	46	6842	17888	34932155
Dopamine dysregulation syndrome	72.24	24.20	17	6871	439	34949604
Akinesia	68.98	24.20	23	6865	2161	34947882
Tremor	65.58	24.20	81	6807	82506	34867537
Impulse-control disorder	63.09	24.20	19	6869	1282	34948761
Gait disturbance	57.38	24.20	77	6811	85063	34864980
Cognitive disorder	56.20	24.20	46	6842	28647	34921396
Dementia	52.27	24.20	33	6855	13715	34936328
Confusional state	52.12	24.20	98	6790	144062	34805981
Aggression	49.62	24.20	49	6839	38915	34911128
Stoma site discharge	47.34	24.20	15	6873	1198	34948845
Agitation	43.44	24.20	55	6833	57344	34892699
Paranoia	41.02	24.20	27	6861	12041	34938002
Reduced facial expression	40.56	24.20	13	6875	1078	34948965
Therapeutic product effect variable	40.48	24.20	16	6872	2440	34947603
Device dislocation	39.83	24.20	21	6867	6228	34943815
Delirium	39.54	24.20	46	6842	43945	34906098
Compulsive shopping	38.42	24.20	10	6878	394	34949649
Posture abnormal	38.35	24.20	15	6873	2224	34947819
Hyperkinesia	38.07	24.20	14	6874	1754	34948289
Pneumonia aspiration	37.97	24.20	44	6844	41859	34908184
Psychotic disorder	37.32	24.20	34	6854	24418	34925625
Therapeutic response shortened	36.49	24.20	21	6867	7383	34942660
Stereotypy	36.45	24.20	11	6877	747	34949296
Persecutory delusion	36.29	24.20	15	6873	2565	34947478
Abnormal behaviour	34.78	24.20	33	6855	24936	34925107
Therapeutic product effect decreased	34.05	24.20	38	6850	34705	34915338
Sudden onset of sleep	33.73	24.20	9	6879	391	34949652
Stoma site pain	33.21	24.20	10	6878	674	34949369
Mania	31.65	24.20	21	6867	9490	34940553
Psychomotor hyperactivity	31.42	24.20	21	6867	9601	34940442
Illusion	31.34	24.20	10	6878	817	34949226
Irritability	31.32	24.20	31	6857	24659	34925384
Device issue	31.12	24.20	21	6867	9756	34940287
Jealous delusion	30.99	24.20	8	6880	305	34949738
Abnormal dreams	30.84	24.20	19	6869	7559	34942484
Obsessive-compulsive disorder	30.72	24.20	17	6871	5547	34944496
Mobility decreased	29.60	24.20	33	6855	30095	34919948
Balance disorder	29.24	24.20	38	6850	40616	34909427
Parkinsonism hyperpyrexia syndrome	29.03	24.20	6	6882	83	34949960
Somatic delusion	28.10	24.20	6	6882	98	34949945
Tricuspid valve sclerosis	27.94	24.20	5	6883	30	34950013
Somnolence	27.76	24.20	65	6823	111051	34838992
Sexually inappropriate behaviour	27.09	24.20	8	6880	504	34949539
Stoma site erythema	27.00	24.20	9	6879	844	34949199
Mitral valve sclerosis	26.41	24.20	6	6882	132	34949911
Progressive supranuclear palsy	25.87	24.20	5	6883	48	34949995
Off label use	25.68	24.20	27	6861	419497	34530546
Restlessness	25.18	24.20	28	6860	25454	34924589
Dystonia	24.67	24.20	19	6869	10826	34939217
Anxiety	24.65	24.20	58	6830	99370	34850673
Memory impairment	24.41	24.20	36	6852	43282	34906761
Colitis microscopic	24.38	24.20	11	6877	2326	34947717

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dyskinesia	627.23	24.95	223	8860	44550	79690755
Hallucination	403.53	24.95	196	8887	85549	79649756
Hallucination, visual	332.77	24.95	129	8954	32600	79702705
On and off phenomenon	318.94	24.95	74	9009	3166	79732139
Hypersexuality	245.41	24.95	53	9030	1627	79733678
Gambling disorder	213.91	24.95	49	9034	1977	79733328
Muscle rigidity	193.58	24.95	76	9007	19806	79715499
Freezing phenomenon	148.13	24.95	36	9047	1878	79733427
Delusion	147.36	24.95	63	9020	20360	79714945
Dystonia	144.53	24.95	63	9020	21336	79713969
Impulse-control disorder	140.53	24.95	34	9049	1740	79733565
Therapeutic response shortened	134.83	24.95	55	9028	15808	79719497
Psychotic disorder	134.71	24.95	74	9009	41328	79693977
Dopamine dysregulation syndrome	126.37	24.95	25	9058	492	79734813
Akinesia	110.53	24.95	32	9051	3280	79732025
Compulsive shopping	109.42	24.95	24	9059	792	79734513
Aggression	105.36	24.95	68	9015	50890	79684415
Neuroleptic malignant syndrome	102.92	24.95	54	9029	27505	79707800
Dysphagia	101.79	24.95	95	8988	122041	79613264
Fall	101.48	24.95	191	8892	487438	79247867
Parkinson's disease	97.17	24.95	25	9058	1646	79733659
Stereotypy	95.18	24.95	22	9061	923	79734382
Tremor	90.54	24.95	104	8979	169979	79565326
Bradykinesia	89.85	24.95	34	9049	8009	79727296
Sudden onset of sleep	86.68	24.95	19	9064	625	79734680
Gait disturbance	84.75	24.95	111	8972	207395	79527910
Confusional state	82.04	24.95	137	8946	317860	79417445
Agitation	80.05	24.95	76	9007	99639	79635666
Parkinsonism hyperpyrexia syndrome	79.16	24.95	15	9068	233	79735072
Acute psychosis	78.52	24.95	26	9057	4154	79731151
Mutism	75.09	24.95	22	9061	2350	79732955
Therapeutic product effect variable	74.16	24.95	21	9062	1988	79733317
Stoma site discharge	67.79	24.95	20	9063	2189	79733116
Hyperkinesia	63.62	24.95	20	9063	2709	79732596
Delirium	61.33	24.95	61	9022	84566	79650739
Psychomotor hyperactivity	57.21	24.95	31	9052	16818	79718487
Abnormal behaviour	57.15	24.95	41	9042	36380	79698925
Irritability	57.08	24.95	43	9040	41101	79694204
Orthostatic hypotension	55.23	24.95	48	9035	56116	79679189
Camptocormia	52.56	24.95	12	9071	476	79734829
Cognitive disorder	51.76	24.95	51	9032	69875	79665430
Dementia	51.16	24.95	33	9050	24626	79710679
Logorrhoea	50.74	24.95	19	9064	4346	79730959
Parkinsonian gait	49.40	24.95	13	9070	935	79734370
Persecutory delusion	48.57	24.95	19	9064	4890	79730415
Reduced facial expression	47.18	24.95	16	9067	2749	79732556
Gambling	46.83	24.95	10	9073	290	79735015
Device issue	45.96	24.95	32	9051	27076	79708229
Posture abnormal	45.56	24.95	17	9066	3849	79731456
Energy increased	44.49	24.95	16	9067	3266	79732039
Mania	44.33	24.95	27	9056	18233	79717072
Progressive supranuclear palsy	42.48	24.95	8	9075	120	79735185
Illusion	41.59	24.95	13	9070	1728	79733577
Blood creatine phosphokinase increased	41.29	24.95	44	9039	66046	79669259
Behaviour disorder	40.70	24.95	18	9065	6295	79729010
Paranoia	40.30	24.95	26	9057	19406	79715899
Stoma site pain	39.54	24.95	12	9071	1446	79733859
Pneumonia aspiration	39.06	24.95	43	9040	66924	79668381
Arthralgia	38.49	24.95	9	9074	571794	79163511
Hypomania	37.63	24.95	18	9065	7526	79727779
Torticollis	37.56	24.95	13	9070	2374	79732931
Parkinsonism	36.40	24.95	23	9060	16561	79718744
Impulsive behaviour	35.08	24.95	13	9070	2887	79732418
Jealous delusion	34.93	24.95	8	9075	322	79734983
Resting tremor	34.84	24.95	11	9072	1510	79733795
Restlessness	34.56	24.95	34	9049	46458	79688847
Wrong technique in product usage process	34.00	24.95	42	9041	73833	79661472
Gastric fistula	33.33	24.95	7	9076	187	79735118
Balance disorder	32.93	24.95	48	9035	98809	79636496
Somnolence	31.48	24.95	78	9005	238903	79496402
Sexually inappropriate behaviour	30.94	24.95	8	9075	537	79734768
Depressed level of consciousness	30.85	24.95	46	9037	96606	79638699
Stoma site infection	30.74	24.95	10	9073	1510	79733795
Tricuspid valve sclerosis	30.68	24.95	5	9078	30	79735275
Obsessive-compulsive disorder	29.13	24.95	14	9069	5913	79729392
Femoral neck fracture	27.45	24.95	16	9067	9968	79725337
Neurotransmitter level altered	27.31	24.95	4	9079	10	79735295
Nightmare	27.24	24.95	23	9060	25838	79709467
Device dislocation	27.15	24.95	23	9060	25947	79709358
Deep brain stimulation	27.14	24.95	5	9078	66	79735239
Headache	27.04	24.95	21	9062	653751	79081554
Anxiety	26.51	24.95	75	9008	248437	79486868
Pain	26.20	24.95	25	9058	703777	79031528
Pleurothotonus	25.82	24.95	10	9073	2506	79732799
Stoma site erythema	25.48	24.95	9	9074	1744	79733561
Abnormal dreams	25.48	24.95	16	9067	11396	79723909
Nocturia	25.20	24.95	17	9066	13664	79721641
Obsessive thoughts	25.16	24.95	8	9075	1124	79734181

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N04BX02	NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Other dopaminergic agents
CHEBI has role	CHEBI:35470	central nervous system agents
CHEBI has role	CHEBI:48406	catechol O-methyltransferase inhibitors
CHEBI has role	CHEBI:48407	antiparkinson agent
CHEBI has role	CHEBI:66956	antidyskinetic agent
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D065098	Catechol O-Methyltransferase Inhibitors
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
FDA MoA	N0000175756	Catechol O-Methyltransferase Inhibitors
FDA EPC	N0000175757	Catechol-O-Methyltransferase Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Parkinson's disease	indication	49049000	DOID:14330
Suicidal thoughts	contraindication	6471006
Hallucinations	contraindication	7011001
Dyskinesia	contraindication	9748009
Peptic ulcer	contraindication	13200003	DOID:750
Disorder of lung	contraindication	19829001	DOID:850
Myocardial infarction	contraindication	22298006	DOID:5844
Orthostatic hypotension	contraindication	28651003
Obstruction of bile duct	contraindication	30144000
Depressive disorder	contraindication	35489007
Conduction disorder of the heart	contraindication	44808001
Duodenal ulcer disease	contraindication	51868009	DOID:1724
Diarrhea	contraindication	62315008
Psychotic disorder	contraindication	69322001
Diabetes mellitus	contraindication	73211009	DOID:9351
Gastrointestinal hemorrhage	contraindication	74474003
Open-angle glaucoma	contraindication	84494001	DOID:1067
Kidney disease	contraindication	90708001	DOID:557
Acute disease of cardiovascular system	contraindication	128487001
Seizure disorder	contraindication	128613002
Drug-induced psychosis	contraindication	191483003	DOID:1742
Disease of liver	contraindication	235856003	DOID:409
Retention of urine	contraindication	267064002
Psychoneurotic personality disorder	contraindication	268634009
Malignant melanoma	contraindication	372244006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Cardiovascular event risk	contraindication	395112001
Gastric ulcer	contraindication	397825006	DOID:10808

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.41	acidic
pKa2	13.34	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Catechol O-methyltransferase	Enzyme	P21964	COMT_HUMAN	INHIBITOR	Ki	9.52	SCIENTIFIC LITERATURE	CHEMBL
G-protein coupled receptor 35	GPCR	Q9HC97	GPR35_HUMAN		EC50	5.25	CHEMBL
Alpha-ketoglutarate-dependent dioxygenase FTO	Unclassified	Q9C0B1	FTO_HUMAN		IC50	5.52	CHEMBL
Mitochondrial pyruvate carrier 2	Transporter	O95563	MPC2_HUMAN	INHIBITOR	IC50	6.22	IUPHAR
Catechol O-methyltransferase	Enzyme		COMT_RAT		IC50	7.89	CHEMBL

External reference:

ID	Source
4021181	VUID
N0000148629	NUI
D00781	KEGG_DRUG
4021181	VANDF
C0165921	UMLSCUI
CHEBI:4798	CHEBI
PD9	PDB_CHEM_ID
CHEMBL953	ChEMBL_ID
DB00494	DRUGBANK_ID
C071192	MESH_SUPPLEMENTAL_RECORD_UI
5281081	PUBCHEM_CID
6647	IUPHAR_LIGAND_ID
6812	INN_ID
4975G9NM6T	UNII
227109	RXNORM
66346	MMSL
8477	MMSL
d04460	MMSL
007684	NDDF
116116003	SNOMEDCT_US
387018000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Comtan	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0327	TABLET, FILM COATED	200 mg	ORAL	NDA	25 sections
Stalevo	HUMAN PRESCRIPTION DRUG LABEL	3	0078-0407	TABLET, FILM COATED	200 mg	ORAL	NDA	25 sections
Stalevo	HUMAN PRESCRIPTION DRUG LABEL	3	0078-0408	TABLET, FILM COATED	200 mg	ORAL	NDA	25 sections
Stalevo	HUMAN PRESCRIPTION DRUG LABEL	3	0078-0409	TABLET, FILM COATED	200 mg	ORAL	NDA	25 sections
Stalevo	HUMAN PRESCRIPTION DRUG LABEL	3	0078-0527	TABLET, FILM COATED	200 mg	ORAL	NDA	25 sections
Stalevo	HUMAN PRESCRIPTION DRUG LABEL	3	0078-0544	TABLET, FILM COATED	200 mg	ORAL	NDA	25 sections
Stalevo	HUMAN PRESCRIPTION DRUG LABEL	3	0078-0545	TABLET, FILM COATED	200 mg	ORAL	NDA	25 sections
Carbidopa, Levodopa and Entacapone	HUMAN PRESCRIPTION DRUG LABEL	3	0378-8300	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	24 sections
Carbidopa, Levodopa and Entacapone	HUMAN PRESCRIPTION DRUG LABEL	3	0378-8301	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	24 sections
Carbidopa, Levodopa and Entacapone	HUMAN PRESCRIPTION DRUG LABEL	3	0378-8302	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	24 sections
Carbidopa, Levodopa and Entacapone	HUMAN PRESCRIPTION DRUG LABEL	3	0378-8303	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	24 sections
Carbidopa, Levodopa and Entacapone	HUMAN PRESCRIPTION DRUG LABEL	3	0378-8304	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	24 sections
Carbidopa, Levodopa and Entacapone	HUMAN PRESCRIPTION DRUG LABEL	3	0378-8305	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	24 sections
Entacapone	HUMAN PRESCRIPTION DRUG LABEL	1	0378-9080	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	21 sections
Entacapone	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1830	TABLET, FILM COATED	200 mg	ORAL	ANDA	26 sections
Entacapone	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8298	TABLET	200 mg	ORAL	ANDA	19 sections
Entacapone	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5578	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	13 sections
Carbidopa, Levodopa, and Entacapone	HUMAN PRESCRIPTION DRUG LABEL	3	0781-5613	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	26 sections
Carbidopa, Levodopa, and Entacapone	HUMAN PRESCRIPTION DRUG LABEL	3	0781-5625	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	26 sections
Carbidopa, Levodopa, and Entacapone	HUMAN PRESCRIPTION DRUG LABEL	3	0781-5637	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	26 sections
Carbidopa, Levodopa, and Entacapone	HUMAN PRESCRIPTION DRUG LABEL	3	0781-5641	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	26 sections
Carbidopa, Levodopa, and Entacapone	HUMAN PRESCRIPTION DRUG LABEL	3	0781-5654	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	26 sections
Carbidopa, Levodopa, and Entacapone	HUMAN PRESCRIPTION DRUG LABEL	3	0781-5669	TABLET, FILM COATED	200 mg	ORAL	NDA authorized generic	26 sections
Entacapone	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6822	TABLET, FILM COATED	200 mg	ORAL	ANDA	20 sections
Entacapone	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6822	TABLET, FILM COATED	200 mg	ORAL	ANDA	20 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE	Human Prescription Drug Label	3	16571-689	TABLET, FILM COATED	200 mg	ORAL	ANDA	26 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE	Human Prescription Drug Label	3	16571-690	TABLET, FILM COATED	200 mg	ORAL	ANDA	26 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE	Human Prescription Drug Label	3	16571-691	TABLET, FILM COATED	200 mg	ORAL	ANDA	26 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE	Human Prescription Drug Label	3	16571-692	TABLET, FILM COATED	200 mg	ORAL	ANDA	26 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE	Human Prescription Drug Label	3	16571-693	TABLET, FILM COATED	200 mg	ORAL	ANDA	26 sections